Stock Market & Financial Investment News

News Breaks January 3, 2013 05:41 EDT GEVA Synageva downgraded to Neutral from Overweight at Piper Jaffray Piper Jaffray downgraded Synageva on expectations the stock will be range bound as the Phase III CESD trial progresses. The firm lowered its price target for shares to $57 from $66. News For GEVA From The Last 14 Days Check below for free stories on GEVA the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 20, 2013 07:14 EDT GEVA Synageva says FDA grants 'Breakthrough Therapy' designation to sebelipase alfa Subscribe for More Information May 16, 2013 08:28 EDT GEVA Synageva has a conference call hosted by JPMorgan Subscribe for More Information May 10, 2013 08:05 EDT GEVA Synageva downgraded to Neutral from Overweight at JPMorgan JPMorgan downgraded Synageva citing concerns that the enrollment could be challenging for the sebelipase alfa Phase 3 trial. The firm lowered its price target for shares to $50 from $57. Sign up for a free trial to see the rest of the stories you've been missing.